Genetic testing firm closes drug discovery division and announces plans to prescribe GLP-1 drugs for weight loss via telehealth platform.
In its recent quarterly earnings report, consumer genetic testing company 23andMe revealed that it is making a move into the lucrative GLP-1 space, as it seeks to capitalize on the runaway success of drugs like semaglutide, marketed around the world as Ozempic and Wegovy. The company said it intends to launch a telehealth weight loss membership program by the end of the month, allowing members to be prescribed GLP-1 medications.
In a separate filing with the SEC, the company also revealed it has shut down its drug discovery business, although it will continue development of the two immuno-oncology programs currently in clinical development.
GLP-1 receptor agonists, best known for their efficacy in inducing substantial weight loss and helping combat diabetes, have also been shown to reduce cardiovascular complications and provide neuroprotective effects in human studies, leading to speculation they may be “longevity drugs.”
The new weight loss membership service will be offered via telehealth provider Lemonaid Health, which 23andMe purchased in 2021. The program will offer participants access to prescription GLP-1 medications along with clinical consultations.
The company also revealed it is commencing a “large-scale genetic research study” into GLP-1s that will seek to identify genetic mechanisms that may affect how the drugs work in different people. The effectiveness of GLP-1s varies from person to person, and some individuals experience adverse side effects, ranging from mild gastrointestinal issues to more serious complications such as pancreatitis or kidney problems. The study’s goal is to uncover whether genetics play a significant role in these varying outcomes.
The study will leverage 23andMe’s genetic and phenotypic database, said to be one of the largest in the world, and the study aims to recruit 10,000 participants to investigate the genetic predictors of GLP-1 treatment response. By identifying predictors, it is hoped the research will enable personalized treatment plans based on an individual’s genetic makeup.
Biological age feature added
23andMe also recently introduced a new biological age feature as part of its Total Health subscription. Powered by a machine learning model that analyzes 13 blood-based biomarkers, such as total cholesterol and hemoglobin A1c, the company calculates a numerical representation of a user’s biological age, reflecting the overall wear and tear on the body.
The feature also provides insights into the health of various organs and systems in the body, including the heart, liver and metabolic functions. The company claims its model, based on data from over 200,000 individuals, also performs well across different demographics, including various ages, sexes and ancestries.
While 23andMe’s biological age calculation doesn’t include genetic data, fitness levels or underlying health conditions, the company claims it still offers a valuable snapshot of an individual’s current health – if someone’s biological age is higher than their calendar age, they can identify the biomarkers responsible and use this information as motivation to adopt healthier lifestyle choices.
